Oragenics is paying for a TBI platform with 3.25 million shares of newly created preferred stock — no cash, no upfront milestone, just equity in a company whose market cap sits well under $50 million. That currency choice is the first signal worth scrutinizing. When a clinical-stage company structures a licensing deal entirely in restricted preferred stock convertible one-for-one into common, it is managing dilution optics while preserving what little cash it has for the Phase IIa trial of ONP-002, its intranasal neurosteroid already in the clinic for concussion and mild TBI.
The strategic logic is genuinely interesting, even if the execution risk is substantial. ONP-002 crosses the blood-brain barrier to suppress central neuroinflammation. CardioDialysis works extracorporeally — filtering cytokines, endotoxins, and pathogenic molecules from the bloodstream peripherally, outside the CNS. If the science holds, Oragenics would be attacking the same post-TBI inflammatory cascade from two anatomically distinct angles simultaneously. No FDA-approved pharmacological treatment exists for concussion or mTBI across a population of roughly 69 million annual injuries worldwide, so the unmet need is real. The dual-modality framing is not just marketing; it reflects a legitimate mechanistic gap in how the field has approached TBI recovery, which has historically fixated on the brain while the systemic inflammatory response runs largely unaddressed.
But this is still a letter of intent, non-binding except for exclusivity and confidentiality provisions, with a 90-day target close contingent on due diligence, board approvals, an independent third-party valuation, and NYSE American compliance review. CardioDialysis has not received FDA clearance. Sigyn Therapeutics trades on the OTCQB. The 3% royalty on revenues doesn’t activate until post-clearance commercial sale — a regulatory milestone that is years away at minimum. Oragenics is essentially buying an option on a complementary mechanism using paper it can create without touching its balance sheet.
The one concrete marker that determines whether this LOI becomes anything more than a strategic press release: whether the independent third-party valuation of CardioDialysis supports the share consideration at closing. If that number comes in low relative to the preferred stock issued, shareholder dilution becomes the dominant narrative — and NYSE American’s continued listing compliance review adds a layer of regulatory scrutiny that could kill the deal before it starts.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
